| Exclusion Criteria: | 1) Prior treatment with Femara or Gleevec.
2) Uncontrolled endocrine disorders such as diabetes mellitus, confirmed hypo- or hyperthyroidism, Cushing's Syndrome, Addison's disease (treated or untreated).
3) Patients with unstable angina, or uncontrolled cardiac disease (e.g. Class III or IV New York Heart Association's Functional Classification).
4) Other concurrent malignant disease with the exception of cone-biopsied in situ carcinoma of the cervix uteri, or adequately treated basal or squamous cell carcinoma of the skin, or other curable cancers e.g. Hodgkin's disease or NHL, provided 5 years have elapsed from completion of therapy, and there has been no recurrence.
5) Concomitant treatment with steroids, e.g. glucocorticoids for indications other than cancer, except aerosol for obstructive airways diseases and steroid injection to the joints for treatment of inflammation.
6) Other investigational drugs within the past 3 weeks and the concomitant use of investigational drugs.
7) History of non-compliance to medical regimens and patients who are considered potentially unreliable.
8) Patients with known brain metastasis.
9) Patients with known chronic liver disease (i.e., chronic active hepatitis, and cirrhosis).
10) Patients with known diagnosis of human immunodeficiency virus (HIV) infection.
11) Patients who received chemotherapy within 4 weeks (6 weeks for nitrosourea or mitomycin-C) prior to study entry, unless the disease is rapidly progressing.
12) Patients who previously received radiotherapy to greater than or equal to 25% of the bone marrow.
13) Patients who had a major surgery within 2 weeks prior to study entry. |